Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer

NCT: NCT07645118 · NOT_YET_RECRUITING

NCT IDNCT07645118

StatusNOT_YET_RECRUITING

SponsorDr. Te Vuong (OTHER)

First posted2026-06-12

Last updated2026-06-12

Brief Summary

This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery (TME) to remove rectal cancer.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑